Follicular and other characteristics with Ovaleap (R) (follitropin alfa) in a phase 3 study of infertile women using assisted reproductive technology (ART)

被引：0
|
作者：
Mueller, A. [1 ]
Kuczynski, W. [2 ]
Weiss, H. [3 ]
Bias, P. [1 ]
机构：
[1] Merckle GmbH, Ulm, Germany
[2] Ctr Reprod Med Cryobank, Dept Obstet & Gynaecol, Bialystok, Poland
[3] Teva Global Med Affairs, Petah Tiqwa, Israel
来源：
GIORNALE ITALIANO DI OSTETRICIA E GINECOLOGIA | 2015年 / 37卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
引用
收藏
页码：170 / 170
页数：1
相关论文
共 50 条
  • [1] Safety of Ovaleap® (Follitropin Alfa) in Infertile Women Undergoing Superovulation for Assisted Reproductive Technologies: A Multinational Comparative, Prospective Cohort Study
    Kaplan, Sigal
    Levy-Toledano, Rachel
    Davies, Miranda
    Roy, Debabrata
    Howles, Colin M.
    Lass, Amir
    [J]. FRONTIERS IN ENDOCRINOLOGY, 2021, 12
  • [2] Safety of Ovaleap® (Follitropin Alfa) in infertile women undergoing superovulation for assisted reproductive technologies (SOFIA): A multinational comparative, prospective cohort study
    Kaplan, Sigal
    Toledano, Rachel
    Davies, Miranda
    Roy, Debabrata
    Howles, Colin
    Lass, Amir
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 334 - 334
  • [3] Safety and efficacy findings with multiple cycles of Ovaleap (R) (follitropin alfa) in assisted reproductive technology (art): open-label follow-up to main phase 3 study
    Weiss, H.
    Strowitzki, T.
    Mueller, A.
    Bias, P.
    [J]. GIORNALE ITALIANO DI OSTETRICIA E GINECOLOGIA, 2015, 37 (04): : 215 - 215
  • [4] Immunogenicity assessment of Ovaleap (R) (XM17) recombinant human follicle-stimulating hormone in infertile women undergoing assisted reproductive technology (ART)
    Zou, L.
    Mueller, A.
    Gertz, B.
    Weiss, H.
    Liu, P.
    [J]. GIORNALE ITALIANO DI OSTETRICIA E GINECOLOGIA, 2016, 38 (01): : 233 - 233
  • [5] Effectiveness and safety of follitropin alfa in infertile women using assisted reproductive technology in real-world clinical practice: a multicenter, prospective, open, non-interventional study
    Sydow, P.
    Schneidereit, R.
    Pribbernow, K.
    Keck, C.
    Wiegratz, I.
    [J]. HUMAN REPRODUCTION, 2017, 32 : 460 - 460
  • [6] Immunogenicity assessment of Ovaleap® (XM17) recombinant human follicle-stimulating hormone in infertile women undergoing assisted reproductive technology (ART)
    Zou, Linglong
    Mueller, Arnd
    Gertz, Beate
    Weiss, Herman
    Liu, Patrick
    [J]. GYNECOLOGICAL ENDOCRINOLOGY, 2016, 32 : 147 - 147
  • [7] Safety and efficacy of Ovaleap® (recombinant human follicle-stimulating hormone) for up to 3 cycles in infertile women using assisted reproductive technology: a phase 3 open-label follow-up to Main Study
    Thomas Strowitzki
    Waldemar Kuczynski
    Arnd Mueller
    Peter Bias
    [J]. Reproductive Biology and Endocrinology, 14
  • [8] Safety and efficacy of Ovaleap® (recombinant human follicle-stimulating hormone) for up to 3 cycles in infertile women using assisted reproductive technology: a phase 3 open-label follow-up to Main Study
    Strowitzki, Thomas
    Kuczynski, Waldemar
    Mueller, Arnd
    Bias, Peter
    [J]. REPRODUCTIVE BIOLOGY AND ENDOCRINOLOGY, 2016, 14 : 1 - 14
  • [9] Effectiveness and safety of follitropin alfa (Ovaleap®) for ovarian stimulation using a GnRH antagonist protocol in real-world clinical practice: a multicenter, prospective, open, non-interventional assisted reproductive technology study
    Peter Sydow
    Norbert Gmeinwieser
    Katrin Pribbernow
    Christoph Keck
    Inka Wiegratz
    [J]. Reproductive Biology and Endocrinology, 18
  • [10] Effectiveness and safety of follitropin alfa (Ovaleap®) for ovarian stimulation using a GnRH antagonist protocol in real-world clinical practice: a multicenter, prospective, open, non-interventional assisted reproductive technology study
    Sydow, Peter
    Gmeinwieser, Norbert
    Pribbernow, Katrin
    Keck, Christoph
    Wiegratz, Inka
    [J]. REPRODUCTIVE BIOLOGY AND ENDOCRINOLOGY, 2020, 18 (01)
12345